Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Gyre Therapeutics (GYRE) over the last 16 years, with Sep 2025 value amounting to -$1.2 million.

  • Gyre Therapeutics' Cash from Investing Activities rose 47.76% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.3 million, marking a year-over-year increase of 73.85%. This contributed to the annual value of -$19.9 million for FY2024, which is 0.63% down from last year.
  • Gyre Therapeutics' Cash from Investing Activities amounted to -$1.2 million in Q3 2025, which was up 59.01% from -$3.0 million recorded in Q2 2025.
  • Gyre Therapeutics' Cash from Investing Activities' 5-year high stood at $52.9 million during Q2 2022, with a 5-year trough of -$69.2 million in Q4 2022.
  • In the last 3 years, Gyre Therapeutics' Cash from Investing Activities had a median value of -$3.0 million in 2025 and averaged -$3.8 million.
  • Within the past 5 years, the most significant YoY rise in Gyre Therapeutics' Cash from Investing Activities was 393.94% (2022), while the steepest drop was 2,514.13% (2022).
  • Gyre Therapeutics' Cash from Investing Activities (Quarterly) stood at $2.9 million in 2021, then plummeted by 2,514.13% to -$69.2 million in 2022, then soared by 101.94% to $1.3 million in 2023, then slumped by 249.66% to -$2.0 million in 2024, then surged by 47.76% to -$1.2 million in 2025.
  • Its Cash from Investing Activities stands at -$1.2 million for Q3 2025, versus -$3.0 million for Q2 2025 and $2.0 million for Q1 2025.